
Current Price | $8.22 | Mkt Cap | $3.0B |
---|---|---|---|
Open | $8.24 | P/E Ratio | -15.89 |
Prev. Close | $8.22 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $8.18 - $8.34 | Volume | 1,801,948 |
52-Wk Range | $5.57 - $10.23 | Avg. Daily Vol. | 2,885,075 |
A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
Current Price | $8.22 | Mkt Cap | $3.0B |
---|---|---|---|
Open | $8.24 | P/E Ratio | -15.89 |
Prev. Close | $8.22 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $8.18 - $8.34 | Volume | 1,801,948 |
52-Wk Range | $5.57 - $10.23 | Avg. Daily Vol. | 2,885,075 |
The best Bull and Bear pitches based on recency and number of recommendations.
The C suite has been cleared. Even if lawsuits are pending, the present Valeant is full of new life and ready for a new chapter. From the Bottom Up!
Scam pharmaceutical company, does no R&D, buys other drug companies and jacks up the price of the medicine.
Read the most recent pitches from players about BHC.
Recs
Bausch (BHC) Upgraded to Strong Buy: Here's Why
Zacks Equity Research February 05, 2019
BHC
Trades from $1
Hide Full Article
Bausch Health (BHC - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
As such, the Zacks rating upgrade for Bausch is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Bausch imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate Revisions
As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.
Earnings Estimate Revisions for Bausch
For the fiscal year ending December 2018, this drugmaker is expected to earn $3.81 per share, which is a change of -0.5% from the year-ago reported number.
Analysts have been steadily raising their estimates for Bausch. Over the past three months, the Zacks Consensus Estimate for the company has increased 2.9%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
Recs
Scam pharmaceutical company, does no R&D, buys other drug companies and jacks up the price of the medicine.
Recs
They've had time to correct their mistakes, but can't seem to get the job done. Perhaps they have poor leadership and need to clean house ??
Find the members with the highest scoring picks in BHC.
expatriot08 (< 20) Score: +1,139.70
The Score Leader is the player with the highest score across all their picks in BHC.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
BuyTheDip | 26.55 | 10/2/2009 |
![]() |
3W | $10.66 | -22.06% | +319.04% | +341.10 | 0 Comment | |
TrackDuality | < 20 | 11/6/2009 |
![]() |
5Y | $12.69 | -34.55% | +302.30% | +336.85 | 0 Comment | |
39272x4 | 22.48 | 11/9/2009 |
![]() |
5Y | $13.04 | -36.31% | +296.00% | +332.31 | 0 Comment | |
ZeroDotCom | 24.92 | 10/15/2009 |
![]() |
5Y | $12.40 | -33.00% | +292.98% | +325.98 | 0 Comment | |
FigginsCapital | 76.59 | 12/29/2011 |
![]() |
5Y | $45.96 | -81.93% | +239.94% | +321.87 | 0 Comment | |
ritchey007 | 32.14 | 10/6/2008 |
![]() |
3M | $7.63 | +8.84% | +309.31% | +300.47 | 0 Comment | |
MrOneHundred | 29.55 | 11/19/2012 |
![]() |
NS | $55.48 | -85.03% | +209.99% | +295.02 | 0 Comment | |
SX3Report | 65.41 |
|
![]() |
3M | $50.94 | -83.70% | +203.11% | +286.81 | 0 Comment | |
RafaelCanadaRed | 77.39 | 5/7/2013 |
![]() |
5Y | $73.43 | -88.69% | +163.66% | +252.35 | 0 Comment | |
Dgirrens | 50.14 | 1/28/2014 |
![]() |
1Y | $130.94 | -93.66% | +139.97% | +233.63 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.